Research News for 2008
-
Teen Girls Fear Breast Cancer
A study by Breastcancer.org founder and president Marisa Weiss found that many teen girls worry about breast cancer and think their risk of breast cancer is higher than it really is.
-
Some Moisturizers Contain Estrogen Even Though Ingredients Don’t List It
New research shows that certain skin lotions contain forms of estrogen, even though these ingredients aren't listed on the label.
-
Women Who Don’t Have Abnormal Breast Cancer Gene Don’t Have Higher Risk, Even if Family Member Does
A large, 18-year study suggests that women who have a family member with an abnormal breast cancer gene but don't have an abnormal gene themsevles don't have higher-than-average breast cancer risk.
-
Increased Risk Lowers After Combination Hormone Replacement Therapy is Stopped
New information from the Women's Health Initiative shows that breast cancer risk goes back down 1 to 2 years after combination hormone replacement therapy is stopped.
-
Femara May Improve Survival Compared to Tamoxifen
For the first time, research suggests that the aromatase inhibitor Femara improves overall survival compared to tamoxifen.
-
Aromasin Slightly Better than Tamoxifen at Reducing Recurrence Risk
Research shows that the aromatase inhibitor Aromasin reduces the risk of the cancer coming back somewhat better than tamoxifen in post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Zometa Seems to Improve Response to Chemotherapy
Research suggests that Zometa, a medicine used to strengthen bones, may slow breast cancer growth.
-
Drop in Breast Density Key to Tamoxifen Lowering Risk
A new study suggests that tamoxifen is successful at reducing breast cancer risk only in high-risk women whose breast density decreases by 10% or more during the first year or so of treatment.
-
Femara and Tykerb Combo Better Than Femara Alone for Metastatic Hormone-Receptor-Positive, HER2-Positive Cancers
A new study shows that treating hormone-receptor-positive, HER2-positive metastatic breast cancer with the combination of Femara and Tykerb offers more benefits than Femara alone.
-
Benign Breast Disease Increases Risk, Amount Depends on Other Factors
Benign breast disease increases a woman's risk of breast cancer; the size of the increase depends on the pathology of the benign disease and family breast cancer history.
